Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas
Background and Objectives To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters. Methods An immunohistoc...
Gespeichert in:
| Veröffentlicht in: | Journal of surgical oncology 2004-05, Vol.86 (2), p.84-90 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 90 |
|---|---|
| container_issue | 2 |
| container_start_page | 84 |
| container_title | Journal of surgical oncology |
| container_volume | 86 |
| creator | Poncelet, Christophe Fauvet, Rafaelle Feldmann, Gérard Walker, Francine Madelenat, Patrick Darai, Emile |
| description | Background and Objectives
To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters.
Methods
An immunohistochemical technique, using antibodies against von Willebrand factor (FvW), CD34, CD31, and VEGF, was applied to formalin‐fixed paraffin‐embedded samples of 32 normal myometria, 32 uterine LM, and 12 LMS. MVD was calculated by a digital image analyzer.
Results
Using anti‐FvW, mean ± SD MVD in myometrium, LM, and LMS was 107.0 ± 53.6, 66.2 ± 55.4, and 64.4 ± 44.2, respectively (P = 0.001). MVD was lower in LMS (P = 0.021) and in LM (P = 0.0004) than in normal myometrium. Using anti‐CD34, mean ± SD MVD in myometrium, LM, and LMS was 187.6 ± 91.2, 106.1 ± 55.5, and 114.2 ± 98.8, respectively (P = 0.001). MVD was lower in LMS (P = 0.012) and LM (P = 0.0004) than in normal myometrium. No such differences were found using anti‐CD31 and anti‐VEGF. No correlation was found between MVD and VEGF expression. In women with uterine LMS, low MVD (assessed with anti‐FvW) correlated with recurrence (P = 0.04) and poor overall survival (P = 0.03).
Conclusions
Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti‐FvW or anti‐CD34 antibodies. A reduced MVD, as assessed by FvW staining, has prognostic value in uterine LMS. J. Surg. Oncol. 2004;86:84–90. © 2004 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/jso.20055 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_754879743</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71885467</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3915-d59de7b3afc78e688d84cce4f02a17fbadbf452e1660499080045318f2112e513</originalsourceid><addsrcrecordid>eNp9kc1u1DAURi0EokNhwQsgr0BITWsndmwv0ZQOoIoifjpLy3FuWhcnHuxkpvMSPDNuZ4AVbK4l3_Md2foQek7JMSWkPLlJ4bgkhPMHaEaJqgtFlHyIZnlXFkwocoCepHRDCFGqZo_RAeWUliUnM_TzUwxXQ0ijs3ht_AQ4dHgdBrx03kMTzdDiztgxxCM8P63Y_aRH-O5-bZKdvIkYhjaM1-Cd8fgqhs14vc9guF1FSMlloRvwJvSQp8v7aYToBsAeXOi3IZloQ2_SU_SoMz7Bs_15iL6dvf06f1ecXyzez9-cF7ZSlBctVy2IpjKdFRJqKVvJrAXWkdJQ0TWmbTrGS6B1TZhSRBLCeEVlV-Z_A6fVIXq1865i-DFBGnXvkgXvzQBhSlpwJoUSrMrky_-TVErOapHB1zvQxpBShE6voutN3GpK9F1NOtek72vK7Iu9dGp6aP-S-14ycLIDNs7D9t8m_eHLxW9lsUu4NMLtn4SJ33V-nOB6-XGhq8Xp5eXZ56Vm1S8ZOqx-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71885467</pqid></control><display><type>article</type><title>Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Poncelet, Christophe ; Fauvet, Rafaelle ; Feldmann, Gérard ; Walker, Francine ; Madelenat, Patrick ; Darai, Emile</creator><creatorcontrib>Poncelet, Christophe ; Fauvet, Rafaelle ; Feldmann, Gérard ; Walker, Francine ; Madelenat, Patrick ; Darai, Emile</creatorcontrib><description>Background and Objectives
To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters.
Methods
An immunohistochemical technique, using antibodies against von Willebrand factor (FvW), CD34, CD31, and VEGF, was applied to formalin‐fixed paraffin‐embedded samples of 32 normal myometria, 32 uterine LM, and 12 LMS. MVD was calculated by a digital image analyzer.
Results
Using anti‐FvW, mean ± SD MVD in myometrium, LM, and LMS was 107.0 ± 53.6, 66.2 ± 55.4, and 64.4 ± 44.2, respectively (P = 0.001). MVD was lower in LMS (P = 0.021) and in LM (P = 0.0004) than in normal myometrium. Using anti‐CD34, mean ± SD MVD in myometrium, LM, and LMS was 187.6 ± 91.2, 106.1 ± 55.5, and 114.2 ± 98.8, respectively (P = 0.001). MVD was lower in LMS (P = 0.012) and LM (P = 0.0004) than in normal myometrium. No such differences were found using anti‐CD31 and anti‐VEGF. No correlation was found between MVD and VEGF expression. In women with uterine LMS, low MVD (assessed with anti‐FvW) correlated with recurrence (P = 0.04) and poor overall survival (P = 0.03).
Conclusions
Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti‐FvW or anti‐CD34 antibodies. A reduced MVD, as assessed by FvW staining, has prognostic value in uterine LMS. J. Surg. Oncol. 2004;86:84–90. © 2004 Wiley‐Liss, Inc.</description><identifier>ISSN: 0022-4790</identifier><identifier>EISSN: 1096-9098</identifier><identifier>DOI: 10.1002/jso.20055</identifier><identifier>PMID: 15112250</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; angiogenesis ; Antigens, CD34 - biosynthesis ; CD31 ; CD34 ; Female ; FvW ; Humans ; Immunohistochemistry ; leiomyoma ; Leiomyoma - metabolism ; Leiomyoma - mortality ; Leiomyoma - pathology ; leiomyosarcoma ; Leiomyosarcoma - metabolism ; Leiomyosarcoma - mortality ; Leiomyosarcoma - pathology ; Middle Aged ; myometrium ; Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis ; Prognosis ; Survival Rate ; Uterine Neoplasms - metabolism ; Uterine Neoplasms - mortality ; Uterine Neoplasms - pathology ; Vascular Endothelial Growth Factor A - biosynthesis ; VEGF ; von Willebrand Factor - biosynthesis</subject><ispartof>Journal of surgical oncology, 2004-05, Vol.86 (2), p.84-90</ispartof><rights>Copyright © 2004 Wiley‐Liss, Inc.</rights><rights>Copyright 2004 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3915-d59de7b3afc78e688d84cce4f02a17fbadbf452e1660499080045318f2112e513</citedby><cites>FETCH-LOGICAL-c3915-d59de7b3afc78e688d84cce4f02a17fbadbf452e1660499080045318f2112e513</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjso.20055$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjso.20055$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15112250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poncelet, Christophe</creatorcontrib><creatorcontrib>Fauvet, Rafaelle</creatorcontrib><creatorcontrib>Feldmann, Gérard</creatorcontrib><creatorcontrib>Walker, Francine</creatorcontrib><creatorcontrib>Madelenat, Patrick</creatorcontrib><creatorcontrib>Darai, Emile</creatorcontrib><title>Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas</title><title>Journal of surgical oncology</title><addtitle>J. Surg. Oncol</addtitle><description>Background and Objectives
To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters.
Methods
An immunohistochemical technique, using antibodies against von Willebrand factor (FvW), CD34, CD31, and VEGF, was applied to formalin‐fixed paraffin‐embedded samples of 32 normal myometria, 32 uterine LM, and 12 LMS. MVD was calculated by a digital image analyzer.
Results
Using anti‐FvW, mean ± SD MVD in myometrium, LM, and LMS was 107.0 ± 53.6, 66.2 ± 55.4, and 64.4 ± 44.2, respectively (P = 0.001). MVD was lower in LMS (P = 0.021) and in LM (P = 0.0004) than in normal myometrium. Using anti‐CD34, mean ± SD MVD in myometrium, LM, and LMS was 187.6 ± 91.2, 106.1 ± 55.5, and 114.2 ± 98.8, respectively (P = 0.001). MVD was lower in LMS (P = 0.012) and LM (P = 0.0004) than in normal myometrium. No such differences were found using anti‐CD31 and anti‐VEGF. No correlation was found between MVD and VEGF expression. In women with uterine LMS, low MVD (assessed with anti‐FvW) correlated with recurrence (P = 0.04) and poor overall survival (P = 0.03).
Conclusions
Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti‐FvW or anti‐CD34 antibodies. A reduced MVD, as assessed by FvW staining, has prognostic value in uterine LMS. J. Surg. Oncol. 2004;86:84–90. © 2004 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>angiogenesis</subject><subject>Antigens, CD34 - biosynthesis</subject><subject>CD31</subject><subject>CD34</subject><subject>Female</subject><subject>FvW</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>leiomyoma</subject><subject>Leiomyoma - metabolism</subject><subject>Leiomyoma - mortality</subject><subject>Leiomyoma - pathology</subject><subject>leiomyosarcoma</subject><subject>Leiomyosarcoma - metabolism</subject><subject>Leiomyosarcoma - mortality</subject><subject>Leiomyosarcoma - pathology</subject><subject>Middle Aged</subject><subject>myometrium</subject><subject>Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis</subject><subject>Prognosis</subject><subject>Survival Rate</subject><subject>Uterine Neoplasms - metabolism</subject><subject>Uterine Neoplasms - mortality</subject><subject>Uterine Neoplasms - pathology</subject><subject>Vascular Endothelial Growth Factor A - biosynthesis</subject><subject>VEGF</subject><subject>von Willebrand Factor - biosynthesis</subject><issn>0022-4790</issn><issn>1096-9098</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAURi0EokNhwQsgr0BITWsndmwv0ZQOoIoifjpLy3FuWhcnHuxkpvMSPDNuZ4AVbK4l3_Md2foQek7JMSWkPLlJ4bgkhPMHaEaJqgtFlHyIZnlXFkwocoCepHRDCFGqZo_RAeWUliUnM_TzUwxXQ0ijs3ht_AQ4dHgdBrx03kMTzdDiztgxxCM8P63Y_aRH-O5-bZKdvIkYhjaM1-Cd8fgqhs14vc9guF1FSMlloRvwJvSQp8v7aYToBsAeXOi3IZloQ2_SU_SoMz7Bs_15iL6dvf06f1ecXyzez9-cF7ZSlBctVy2IpjKdFRJqKVvJrAXWkdJQ0TWmbTrGS6B1TZhSRBLCeEVlV-Z_A6fVIXq1865i-DFBGnXvkgXvzQBhSlpwJoUSrMrky_-TVErOapHB1zvQxpBShE6voutN3GpK9F1NOtek72vK7Iu9dGp6aP-S-14ycLIDNs7D9t8m_eHLxW9lsUu4NMLtn4SJ33V-nOB6-XGhq8Xp5eXZ56Vm1S8ZOqx-</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Poncelet, Christophe</creator><creator>Fauvet, Rafaelle</creator><creator>Feldmann, Gérard</creator><creator>Walker, Francine</creator><creator>Madelenat, Patrick</creator><creator>Darai, Emile</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20040501</creationdate><title>Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas</title><author>Poncelet, Christophe ; Fauvet, Rafaelle ; Feldmann, Gérard ; Walker, Francine ; Madelenat, Patrick ; Darai, Emile</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3915-d59de7b3afc78e688d84cce4f02a17fbadbf452e1660499080045318f2112e513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>angiogenesis</topic><topic>Antigens, CD34 - biosynthesis</topic><topic>CD31</topic><topic>CD34</topic><topic>Female</topic><topic>FvW</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>leiomyoma</topic><topic>Leiomyoma - metabolism</topic><topic>Leiomyoma - mortality</topic><topic>Leiomyoma - pathology</topic><topic>leiomyosarcoma</topic><topic>Leiomyosarcoma - metabolism</topic><topic>Leiomyosarcoma - mortality</topic><topic>Leiomyosarcoma - pathology</topic><topic>Middle Aged</topic><topic>myometrium</topic><topic>Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis</topic><topic>Prognosis</topic><topic>Survival Rate</topic><topic>Uterine Neoplasms - metabolism</topic><topic>Uterine Neoplasms - mortality</topic><topic>Uterine Neoplasms - pathology</topic><topic>Vascular Endothelial Growth Factor A - biosynthesis</topic><topic>VEGF</topic><topic>von Willebrand Factor - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poncelet, Christophe</creatorcontrib><creatorcontrib>Fauvet, Rafaelle</creatorcontrib><creatorcontrib>Feldmann, Gérard</creatorcontrib><creatorcontrib>Walker, Francine</creatorcontrib><creatorcontrib>Madelenat, Patrick</creatorcontrib><creatorcontrib>Darai, Emile</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poncelet, Christophe</au><au>Fauvet, Rafaelle</au><au>Feldmann, Gérard</au><au>Walker, Francine</au><au>Madelenat, Patrick</au><au>Darai, Emile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas</atitle><jtitle>Journal of surgical oncology</jtitle><addtitle>J. Surg. Oncol</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>86</volume><issue>2</issue><spage>84</spage><epage>90</epage><pages>84-90</pages><issn>0022-4790</issn><eissn>1096-9098</eissn><abstract>Background and Objectives
To compare uterine leiomyosarcomas (LMS) and leiomyomas (LM) with normal myometrium in terms of microvessel density (MVD), and to correlate this parameter with vascular endothelial growth factor (VEGF) expression and clinical/pathological parameters.
Methods
An immunohistochemical technique, using antibodies against von Willebrand factor (FvW), CD34, CD31, and VEGF, was applied to formalin‐fixed paraffin‐embedded samples of 32 normal myometria, 32 uterine LM, and 12 LMS. MVD was calculated by a digital image analyzer.
Results
Using anti‐FvW, mean ± SD MVD in myometrium, LM, and LMS was 107.0 ± 53.6, 66.2 ± 55.4, and 64.4 ± 44.2, respectively (P = 0.001). MVD was lower in LMS (P = 0.021) and in LM (P = 0.0004) than in normal myometrium. Using anti‐CD34, mean ± SD MVD in myometrium, LM, and LMS was 187.6 ± 91.2, 106.1 ± 55.5, and 114.2 ± 98.8, respectively (P = 0.001). MVD was lower in LMS (P = 0.012) and LM (P = 0.0004) than in normal myometrium. No such differences were found using anti‐CD31 and anti‐VEGF. No correlation was found between MVD and VEGF expression. In women with uterine LMS, low MVD (assessed with anti‐FvW) correlated with recurrence (P = 0.04) and poor overall survival (P = 0.03).
Conclusions
Uterine smooth muscle tumors exhibit a lower MVD than normal myometrium, as assessed using anti‐FvW or anti‐CD34 antibodies. A reduced MVD, as assessed by FvW staining, has prognostic value in uterine LMS. J. Surg. Oncol. 2004;86:84–90. © 2004 Wiley‐Liss, Inc.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>15112250</pmid><doi>10.1002/jso.20055</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4790 |
| ispartof | Journal of surgical oncology, 2004-05, Vol.86 (2), p.84-90 |
| issn | 0022-4790 1096-9098 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_754879743 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adult Aged Aged, 80 and over angiogenesis Antigens, CD34 - biosynthesis CD31 CD34 Female FvW Humans Immunohistochemistry leiomyoma Leiomyoma - metabolism Leiomyoma - mortality Leiomyoma - pathology leiomyosarcoma Leiomyosarcoma - metabolism Leiomyosarcoma - mortality Leiomyosarcoma - pathology Middle Aged myometrium Platelet Endothelial Cell Adhesion Molecule-1 - biosynthesis Prognosis Survival Rate Uterine Neoplasms - metabolism Uterine Neoplasms - mortality Uterine Neoplasms - pathology Vascular Endothelial Growth Factor A - biosynthesis VEGF von Willebrand Factor - biosynthesis |
| title | Prognostic value of von Willebrand factor, CD34, CD31, and vascular endothelial growth factor expression in women with uterine leiomyosarcomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T00%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20von%20Willebrand%20factor,%20CD34,%20CD31,%20and%20vascular%20endothelial%20growth%20factor%20expression%20in%20women%20with%20uterine%20leiomyosarcomas&rft.jtitle=Journal%20of%20surgical%20oncology&rft.au=Poncelet,%20Christophe&rft.date=2004-05-01&rft.volume=86&rft.issue=2&rft.spage=84&rft.epage=90&rft.pages=84-90&rft.issn=0022-4790&rft.eissn=1096-9098&rft_id=info:doi/10.1002/jso.20055&rft_dat=%3Cproquest_cross%3E71885467%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71885467&rft_id=info:pmid/15112250&rfr_iscdi=true |